Table 5.
Evaluation of four biomarkers for PD motor progression
| Progression (n = 17) | Non-progression (n = 22) | HR (95% CI) | p value | |
|---|---|---|---|---|
| Age (y) | 68.0 ± 6.7 | 68.8 ± 8.5 | / | 0.75 |
| Sex, N | ||||
| Male | 12 | 14 | / | 0.74 |
| Female | 5 | 8 | ||
| CX3CL1 | ||||
| Decreased | 9 | 4 | 2.86 (1.08–7.69) | 0.036 |
| Increased | 8 | 18 | ||
| IL-8 | ||||
| Increased | 7 | 13 | 0.44 (0.16–1.88) | 0.10 |
| Decreased | 10 | 9 | ||
| CXCL12 | ||||
| Increased | 2 | 7 | 0.53 (0.12–2.34) | 0.40 |
| Decreased | 15 | 15 | ||
| MIP-5 | ||||
| Increased | 12 | 19 | 1.09 (0.37–3.24) | 0.88 |
| Decreased | 7 | 3 | ||
Cox proportional hazards regression models were used to estimate HRs, with 95% CI adjusted for age and sex
The bold emphasis in the table means p < 0.05
HR hazard ratio, 95 CI 95 confidence interval